This Is MS Multiple Sclerosis Community: Knowledge & Support

here is an important paragraph from their press release -- you can find the whole release on their site at http://www.nutrapharma.com --

The study was conducted by researchers in the Department of Anatomy and Cell Biology at the University of Saskatchewan. The lead researcher, Associate Professor Dr. Adel Mohamed, reported that the preliminary results indicate that RPI-78M inhibited the development of acute as well as the relapsing phases of the EAE in Lewis rats. The report also stated that, if confirmed, these preliminary results suggest that it is of interest to initiate clinical trials on MS patients using the drug. The conclusion of the report stated that it seems within the realm of possibility that RPI-78M may be as, if not more, therapeutically efficacious as the current interferon drugs in the treatment of neurologic disease.

This, this is kind of disappointing. Usually in pre-clinical studies, the companies are bragging about how their drug completely halts EAE, and maybe even reverses some damage. Those drugs often end-up crapping out of human trials anyway. But if the best Nutra Pharma can say is that it might be equal or better than the CRABs, that doesn't seem like a very good start.

I would say that they are being conservative -- the EAE study is an important first step to show reasoning to the FDA to do a phase II trial -- I would be disappointed if they had said that it is not effective....in the EAE, they just need to show safety and efficacy

Don't get me wrong, I'm glad that nothing has stopped its progress in trials so far. It's just that we all love to hate the CRABs and now I'm not all that optimistic about this one being better than the CRABs. They have to do the trials to find out for sure, so only time will tell.